Friday 6 November 2026
Export GLAS’s income statement to Excel — free account
Glass House Brands Inc.
GLAS Healthcare Drug Manufacturers Specialty & Generic
Glass House Brands Inc.’s revenue for fiscal 2025 (year ended December 2025) was $182.0 million, down 9.41% from fiscal 2024.
- Revenue
- −1.24%
- EPS
- −320.0%
- Free cash flow
- −123.4%
- Total debt
- −17.2%
Quarter to June 2026, against a year earlier
2.04
0.19
−8.52%
Follow GLAS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (74.02%) | (59.17%) | (56.40%) | (17.99%) |
+7 more TTM periods Free account |
|
| (19.78%) | (15.84%) | (14.33%) | (4.51%) | ||
ROIC |
(23.36%) | (13.43%) | (7.45%) | (1.00%) | |
Return on Tangible Assets |
(26.82%) | (19.13%) | (18.38%) | (5.34%) | |
Average Days of Receivables |
22.32 | 14.80 | 10.41 | 15.90 | |
Free Cash Flow per Share |
(0.41) | (0.31) | (0.19) | (0.05) | |
Free Cash Flow |
(36.80) | (26.59) | (15.51) | (4.00) | |
Capital Expenditures |
(16.46) | (23.81) | (26.96) | (27.34) | |
| Other line items | |||||
Cash ROIC |
(25.05%) | (14.93%) | (9.48%) | (2.15%) | |
Accounts Receivable Turnover |
16.39 | 22.42 | 29.49 | 30.68 | |
Accounts Payable Turnover |
3.19 | 3.22 | 3.54 | 3.71 | |
Inventory Turnover |
4.49 | 4.69 | 5.45 | 7.32 | |
Average Days of Payables |
115.27 | 125.44 | 98.19 | 101.67 | |
Days of Inventory on Hand |
103.07 | 103.92 | 84.45 | 68.49 | |
Tax Rate |
0.29 | 0.51 | 0.70 | (1.35) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
40.52% | 38.54% | 36.69% | 32.44% | |
Share Based Compensation of Revenue |
9.65% | 8.90% | 7.36% | 6.73% | |
Interest Coverage |
(8.51) | (4.57) | (2.34) | (0.26) | |
Operating CF/Net income |
0.32 | 0.06 | (0.25) | (1.66) | |
Depreciation/Fixed assets |
0.07 | 0.07 | 0.07 | 0.07 | |
Capex/Depreciation |
(1.04) | (1.49) | (1.71) | (1.75) | |
Revenue per Share |
2.00 | 2.04 | 2.22 | 2.23 | |
Operating CF per Share |
(0.23) | (0.03) | 0.14 | 0.28 | |
Capex per Share |
(0.19) | (0.27) | (0.33) | (0.33) | |
Capex to Sales |
0.09 | 0.13 | 0.15 | 0.15 |
Columns are period end dates · fundamentals updated 2 Nov 2026